Liangru Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liangru Lin has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Guangjun Nie
National Center for Nanoscience and Technology
1 shared publication Hanqing Chen
Department of Gastroenterology Guangzhou Digestive Disease Center Guangzhou First People’s Hospital School of Medicine South China University of Technology Guangzhou China
1 shared publication- Motao Zhu
CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China
1 shared publication Ruifang Zhao
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center of Excellence in Nanoscience National Center for Nanoscience and Technology Beijing China
1 shared publication
Latest Publications
- Open Access
- 28 December 2021
- Published by Wiley in Cancer Science
- Vol. 113 (3) , 828-837
Nanomedicine targets iron metabolism for cancer therapy
Iron is an essential element for cell proliferation and homeostasis via engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling, while iron overload may contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) antibodies, and cytotoxic ligands conjugated to transferrin, has become a considera.
- 28 December 2021
- Published by Wiley in Cancer Science
- Vol. 113 (3) , 828-837
Open AccessNanomedicine targets iron metabolism for cancer therapy
Iron is an essential element for cell proliferation and homeostasis via engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling, while iron overload may contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) antibodies, and cytotoxic ligands conjugated to transferrin, has become a considera.